vatalanib has been researched along with Neuralgia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bates, DO; Donaldson, LF; Drake, RA; Hulse, RP | 1 |
| Li, G; Liang, S; Liu, H; Liu, S; Peng, H; Qiu, S; Tu, G; Xie, J; Xu, C | 1 |
2 other study(ies) available for vatalanib and Neuralgia
| Article | Year |
|---|---|
The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain.
Topics: Alternative Splicing; Animals; Antibodies; Disease Models, Animal; Functional Laterality; Hyperalgesia; Male; Myelin Sheath; Nerve Fibers, Myelinated; Neuralgia; Pain Measurement; Phthalazines; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Wistar; Sensory Receptor Cells; Serine-Arginine Splicing Factors; Spinal Cord; Time Factors; Vascular Endothelial Growth Factor A; Vesicular Glutamate Transport Protein 1 | 2016 |
Vatalanib decrease the positive interaction of VEGF receptor-2 and P2X2/3 receptor in chronic constriction injury rats.
Topics: Animals; Chronic Pain; Disease Models, Animal; Male; Neuralgia; Phthalazines; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2X2; Receptors, Purinergic P2X3; Vascular Endothelial Growth Factor Receptor-2 | 2012 |